What is palmitoylethanolamide?

The short answer

Palmitoylethanolamide — PEA — is a fatty-acid amide that the human body makes for itself. It is the amide of palmitic acid and ethanolamine, chemically N-(2-hydroxyethyl)hexadecanamide, CAS number 544-31-0. Cells across essentially every tissue synthesise it on demand when they are injured or stressed, and it works principally by activating a nuclear receptor called PPAR-alpha, which changes which inflammatory genes the cell transcribes.

It is not a cannabinoid. It is not a plant extract. It is not psychoactive. It has been in the scientific literature since 1957 and in commercial products since the 1970s, and it is now one of the better-evidenced ingredients in the pain and inflammation category — with a safety profile that most pharmaceuticals in the same space cannot approach.

Chemistry and identity

Structurally, PEA sits in the same family as anandamide and oleoylethanolamide — a saturated sixteen-carbon tail attached through an amide bond to an ethanolamine head. That saturated tail is why PEA is not a cannabinoid receptor ligand while anandamide, with its four double bonds, is.

Where it came from

1954. Coburn and colleagues observed that dietary egg yolk protected guinea pigs from experimentally induced inflammatory arthritis.

1957. Kuehl and colleagues at the Merck Institute isolated the responsible molecule from egg yolk phospholipid and identified it as N-(2-hydroxyethyl)-palmitamide, publishing in the Journal of the American Chemical Society.

1958. The same compound was recovered from peanut meal and soybean lecithin.

1970s. Marketed as Impulsin in Czechoslovakia for respiratory infection prophylaxis and as Palmidrol in Spain. Six double-blind placebo-controlled trials ran between 1972 and 1977 across 3,627 subjects.

1993. Rita Levi-Montalcini's group proposed the ALIA hypothesis — Autacoid Local Injury Antagonism — naming PEA and its relatives ALIAmides and framing them as locally produced agents that restrain mast-cell-driven injury responses.

2005. LoVerme and colleagues identified PPAR-alpha as the receptor mediating PEA's anti-inflammatory action, giving the field a molecular target and triggering the modern wave of research.

How it works

Four mechanisms, in descending order of how well established they are.

PPAR-alpha agonism — the primary mechanism

PPAR-alpha is a ligand-activated transcription factor. PEA binds it, PPAR-alpha pairs with the retinoid X receptor, moves into the nucleus, and changes gene transcription. The consequence is reduced expression of COX-2 and iNOS, less pro-inflammatory cytokine output, and suppression of NF-kappaB nuclear translocation.

The proof that this is the mechanism is genetic: in PPAR-alpha knockout mice, PEA's anti-inflammatory, analgesic and neuroprotective effects vanish. Block the receptor pharmacologically and you get the same result.

Note the mechanistic distinction from an NSAID. An NSAID inhibits COX enzyme that already exists; PEA reduces how much COX-2 the cell builds in the first place. That difference is what explains the slower onset. It is a statement about mechanism, not a comparative safety claim — no controlled head-to-head trial against an NSAID has been published.

The ALIA mechanism — mast cells and glia

Mast cells sit at the interface between tissue injury and inflammation. When they degranulate they release histamine, prostaglandins, cytokines and nerve growth factor, sensitising nearby pain fibers. PEA restrains that degranulation — demonstrated in allergen-challenged canine skin mast cells across a 10⁻⁸ to 10⁻⁶ M concentration range. The same logic applies centrally to microglia and astrocytes, whose over-activation is now understood to be part of how acute pain becomes chronic.

The entourage effect — and what PEA does not do

PEA does not bind CB1 or CB2 receptors to any meaningful degree. What it does is compete for fatty acid amide hydrolase, the enzyme that breaks down anandamide, thereby sparing anandamide and prolonging its cannabinoid receptor signalling. It also raises 2-arachidonoylglycerol levels and increases CB2 receptor expression downstream of PPAR-alpha. So it modulates endocannabinoid tone without being a cannabinoid itself.

TRPV1 desensitization

PEA both activates and desensitizes TRPV1, the capsaicin receptor on sensory neurons, through a PPAR-alpha-dependent route. Repeated exposure leaves the channel less responsive to noxious stimuli.

What the clinical evidence shows

Seven meta-analyses and systematic reviews have been published since 2016. The two strongest, methodologically:

• Lang-Illievich et al., 2023 (Nutrients) pooled eleven double-blind randomized controlled trials covering 774 patients across doses of 300–1200 mg/day, finding a standardized mean difference of 1.68 for pain intensity, with improvements also in quality of life, function and sleep.
• Viña and López-Moreno, 2025 (Nutrition Reviews) pooled eighteen RCTs and 1,196 patients, finding an SMD of −0.90 at six weeks deepening to −1.16 at 24–26 weeks, and effects sustained across nociceptive, neuropathic and nociplastic pain.

Beyond the pooled data, the individual trials with the strongest results are in nerve compression pain (636 patients, VAS 7.1 to 2.1 at 600 mg/day, NNT of 1.5), knee osteoarthritis (111 patients, significant WOMAC and NRS improvement at both 300 and 600 mg/day) and diabetic peripheral neuropathy (66 patients, quadruple-blind, significant improvement across pain, sleep and IL-6).

Safety

This is where PEA is genuinely unusual. A GLP-compliant OECD Test Guideline 414 developmental toxicity study in pregnant rats found no adverse effects at any dose up to 1,000 mg/kg/day — the highest tested — giving a NOAEL above that figure. A review of sixteen clinical trials covering roughly 1,590 patients concluded that for treatment courses up to 49 days the pooled data exclude serious adverse reactions occurring at a rate of one in 200 or more. Pooled dropout ran lower on PEA than on placebo, approximately 1.1% versus 4.3%.

Reported adverse events are mild and infrequent: occasional gastrointestinal discomfort, transient drowsiness, headache, isolated palpitations.

The genuine gaps: no human data in pregnancy or lactation; no controlled data beyond twelve months; no published pharmacokinetic drug-interaction studies.

Doses used in trials

Most human studies use 300 to 1,200 mg per day. The single most common regimen is 300 mg twice daily. Some protocols load at 1,200 mg/day for the first month and step down to 600 mg/day for maintenance.

The most practically useful finding is about duration. A 2024 extended-treatment meta-analysis found roughly 60% of the total pain reduction accruing in month one, with a further 1.36-point reduction between day 30 and day 60. Evaluating PEA over only 30 days therefore under-reads the published effect.

Full dosage guide

Micronized, ultra-micronized and why it matters

PEA is practically insoluble in water with a log P around 6. Absorption is limited by dissolution rate, which scales with surface area, which means particle size is the biggest formulation variable there is.

The cleanest evidence: in a rat inflammatory pain model, orally administered micronized and ultra-micronized PEA significantly reduced edema and hyperalgesia while unmicronized PEA did not — but given intraperitoneally, bypassing the gut, all three worked equally. The gap is absorption, not pharmacology.

The honest counterweight: in beagles at 15 mg/kg, micronized and ultra-micronized PEA gave essentially identical serum peaks. The reproducible step change is unmicronized to micronized; beyond that, returns diminish.

The full particle-size analysis

Natural occurrence

PEA is present in soy lecithin at around 950,000 ng/g, in raw peanuts at around 7,800 ng/g, in green coffee at 2,800–11,900 ng/g, and in egg, chicken, tuna and various vegetables at roughly 90–130 ng/g. Even at the top of that range you would need to eat well over 400 g of soy lecithin to reach a 400 mg dose, which is why supplementation exists.

In the body it has been detected in muscle, spleen, eye, gut, spinal cord, skin, heart, blood, adipose tissue, brain and reproductive fluids.

How PEA is made and supplied commercially

Extraction from natural sources is not economic at scale, so all commercial PEA is synthesized — by condensing palmitic acid with ethanolamine to form the amide bond. Where the palmitic acid comes from determines whether the finished material supports a vegan claim; vegetable-derived feedstock does, tallow-derived does not.

After synthesis comes crystallization, drying, and for micronized grades, jet milling. Jet milling reduces particle size by particle-on-particle collision in a high-velocity gas stream, without mechanical grinding surfaces and without significant heat input — which matters for a solid melting just below 100 °C. The published literature describes PEA as difficult to micronise, which is why the milling step, rather than the chemistry, is where suppliers genuinely differ.

How PEAOID is manufactured

Regulatory position

Status differs sharply by market. In India, PEA has been approved repeatedly under the Non-Specified Food and Food Ingredients Regulations, with eleven approvals to Indian applicants between 2018 and 2025 — though these are applicant-specific rather than a blanket clearance. Australia's TGA permits it as an active in listed medicines. Health Canada has licensed natural health products containing it. Italy is the most mature market, with PEA long established as a food for special medical purposes. In the United States it is sold as a dietary-supplement ingredient. In the EU, no bloc-wide novel food authorization has been confirmed and the position varies nationally.

Full regulatory detail by market